Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
GSK axes $625M TIGIT drug as midphase data disappoint
GSK and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival fell short of expectations.
Nick Paul Taylor
May 13, 2025 9:44am
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
Apr 28, 2025 7:25am
Apollomics tags out of TYG oncology pact to cut costs
Apr 4, 2025 6:45am
BioNTech posts survival data behind bispecific's phase 3 push
Mar 28, 2025 8:00am
ImmuneOnco axes CD47 bispecific amid pipeline prioritization
Mar 26, 2025 6:21am
Pfizer to test Summit's white-hot bispecific with ADCs
Feb 24, 2025 9:17am
